Autres langues Esperion Therapeutics, Inc.

Actions

ESPR

US29664W1053

Marché Fermé - Nasdaq Autres places de cotation 22:00:01 23/04/2024			Varia. 5j.	Varia. 1 janv.
2,08 ^USD	+8,90 %		+8,90 %	-30,43 %

25/03	Mise à jour sectorielle : Les actions du secteur de la santé sont stables en pré-marché lundi	MT
25/03	Transcript : Esperion Therapeutics, Inc. - Special Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Esperion to Report First Quarter 2024 Financial Results on May 7	23/04
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL Tablets in Diverse Populations Including Women, Hispanics, Latinx and Patients with Obesity	08/04
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	07/04
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity	07/04
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024	01/04
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be presented at ACC.24	26/03
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference	26/03
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	25/03
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24	25/03
Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	25/03
Sector Update: Health Care Stocks Steady Premarket Monday	25/03
Esperion - U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	25/03
Esperion - CHMP Issues Positive Opinions for both Bempedoic Acid and the Bempedoic Acid, Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events	25/03
Top Premarket Gainers	25/03
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	22/03
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	22/03
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	22/03
Esperion Says FDA Approves New Labels for Nexletol and Nexlizet	22/03
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	22/03
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	22/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Esperion Therapeutics, Inc.

Actions

ESPR

US29664W1053

Autres langues

Filtres